Botanix Pharmaceuticals
11
0
0
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
27%
3 trials in Phase 3/4
91%
10 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301)
Role: lead
Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302)
Role: lead
A Non-Interventional Study To Assess Sweating
Role: lead
A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 Gel in Subjects With Palmar Hyperhidrosis
Role: lead
A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis
Role: lead
A Confirmatory Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
Role: lead
A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
Role: lead
A Safety Study of BBI-4000 Gel in Pediatric Patients With Axillary Hyperhidrosis
Role: lead
A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
Role: lead
Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis
Role: lead
Evaluation of BTX 1503 in Patients With Moderate to Severe Acne Vulgaris
Role: lead
All 11 trials loaded